Oncology – Page 12

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

By MedXY 08/05/2025

A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.

Clinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY 08/05/2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.

$A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children$

Clinical Updates news Oncology Specialties

A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children

By MedXY 08/05/2025

A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.

Clinical Updates news Oncology Specialties

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

By MedXY 08/05/2025

A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.

Clinical Updates news Oncology Specialties

Cannabis Use Disorder Linked to Elevated Risk of Benign Salivary Gland Tumors: New Insights from a Large Retrospective Cohort Study

By MedXY 08/04/2025

A large US-based study found a greater than fivefold increased risk of benign salivary gland tumors, especially parotid tumors, in individuals with cannabis use disorder.

Clinical Updates news Oncology Specialties

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

By MedXY 08/03/2025

Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.

Medical News news Oncology Specialties

Is Your Practice Missing the Next Gastric Cancer Surge?

By MedXY 08/03/2025

A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.

Clinical Updates news Oncology Specialties

Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors

By MedXY 08/03/2025

A comprehensive analysis reveals that radiotherapy, chemotherapy, and genetic factors substantially contribute to subsequent neoplasms in long-term childhood cancer survivors, while lifestyle factors play a minimal role.

Clinical Updates news Oncology Specialties Urology

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

By MedXY 08/03/2025

The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.

Clinical Updates news Oncology Specialties

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

By MedXY 08/03/2025

The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

By MedXY 08/03/2025

Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.

Clinical Updates news Oncology Specialties

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

By MedXY 08/03/2025

Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.

Clinical Updates news Oncology Specialties

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY 08/03/2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates news Oncology Radiology Specialties Urology

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates news Oncology Specialties

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

By MedXY 08/03/2025

The IMPORT LOW trial confirms that partial-breast and reduced-dose radiotherapy are as effective and safe as whole-breast radiotherapy for selected women with early breast cancer, supporting their use as standard care.

Clinical Updates news Oncology Specialties

Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study

By MedXY 08/03/2025

Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.

Clinical Updates news Oncology Specialties

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.

$Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study$

Clinical Updates news Oncology Specialties

Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study

By MedXY 08/02/2025

FT516, an iPSC-derived NK cell therapy, shows promising safety and efficacy in relapsed or refractory B-cell lymphoma, potentially overcoming key limitations of existing cell therapies.

Clinical Updates news Oncology Specialties

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

By MedXY 08/02/2025

Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.